key: cord-0945453-bbe76fau
authors: Ishigaki, Hirohito; Nakayama, Misako; Kitagawa, Yoshinori; Nguyen, Cong Thanh; Hayashi, Kaori; Shiohara, Masanori; Gotoh, Bin; Itoh, Yasushi
title: Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques
date: 2020-08-19
journal: bioRxiv
DOI: 10.1101/2020.08.18.256446
sha: 0afdc5997be451df31747c108d57d7d1bc43265c
doc_id: 945453
cord_uid: bbe76fau

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infectious disease (COVID-19) has been threatening the world because of severe symptoms and relatively high mortality. To develop vaccines and antiviral drugs for COVID-19, an animal model of SARS-CoV-2 infection is required to evaluate the efficacy of prophylactics and therapeutics in vivo. Therefore, we examined the pathogenicity of SARS-CoV-2 in cynomolgus macaques until 28 days after virus inoculation in the present study. Cynomolgus macaques showed body temperature rises after infection and X-ray radiographic viral pneumonia was observed in one of three macaques. However, none of the macaques showed life-threatening clinical signs of disease corresponding that approximately 80% of human patients did not show a critical disease in COVID-19. A neutralizing antibody against SARS-CoV-2 and T-lymphocytes that produced interferon (IFN)-γ and interleukin (IL)-2 specifically for SARS-CoV-2 N protein were detected on day 14 in the macaque that showed viral pneumonia. On the other hand, in the other macaques, in which a neutralizing antibody was not detected, T-lymphocytes that produced IFN-γ specifically for SARS-CoV-2 N protein increased on day 7 to day 14 prior to an increase in the number of T-lymphocytes that produced IL-2. These results suggest that not only a neutralizing antibody but also cellular immunity augmented by IFN-γ has a role in the elimination of SARS-CoV-2. Thus, because of the mild clinical signs of disease and low/no antibody responses against SARS-CoV-2 in two thirds of the macaques, cynomolgus macaques are appropriate to extrapolate human responses in vaccine and drug development. Author Summary Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infectious disease (COVID-19) has been threatening the world. To develop vaccines and antiviral drugs for COVID-19, an animal model of SARS-CoV-2 infection is required to evaluate their efficacy in vivo. Therefore, we examined the pathogenicity of SARS-CoV-2 in a non-human primate model until 28 days after virus inoculation. Cynomolgus macaques showed a fever after infection and X-ray radiographic viral pneumonia was observed in one of three macaques. However, none of the macaques showed life-threatening symptoms. A neutralizing antibody against SARS-CoV-2 and T-lymphocytes that produced interferon (IFN)-γ and interleukin (IL)-2 specifically for SARS-CoV-2 protein were detected on day 14 in the macaque that showed viral pneumonia. In the other macaques, in which a neutralizing antibody was not detected, T-lymphocytes that produced IFN-γ specifically for SARS-CoV-2 N protein increased on day 7 to day 14. These results suggest that not only a neutralizing antibody but also cellular immunity augmented by IFN-γ has a role in the elimination of SARS-CoV-2. Thus, because of the mild symptoms and low/no antibody responses against SARS-CoV-2 in two thirds of the macaques, cynomolgus macaques are appropriate to extrapolate human responses in vaccine and drug development.

none of the macaques showed life-threatening clinical signs of disease corresponding that 23 approximately 80% of human patients did not show a critical disease in COVID-19. A neutralizing 24 antibody against SARS-CoV-2 and T-lymphocytes that produced interferon (IFN)-γ and interleukin 25 (IL)-2 specifically for SARS-CoV-2 N protein were detected on day 14 in the macaque that showed 26 viral pneumonia. On the other hand, in the other macaques, in which a neutralizing antibody was 27 not detected, T-lymphocytes that produced IFN-γ specifically for SARS-CoV-2 N protein increased 28 on day 7 to day 14 prior to an increase in the number of T-lymphocytes that produced IL-2. These 29 results suggest that not only a neutralizing antibody but also cellular immunity augmented by IFN-γ 30 has a role in the elimination of SARS-CoV-2. Thus, because of the mild clinical signs of disease and 31 low/no antibody responses against SARS-CoV-2 in two thirds of the macaques, cynomolgus 32 macaques are appropriate to extrapolate human responses in vaccine and drug development. 33

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infectious disease (COVID-19) 36 has been threatening the world. To develop vaccines and antiviral drugs for COVID-19, an animal 37 model of SARS-CoV-2 infection is required to evaluate their efficacy in vivo. Therefore, we 38 examined the pathogenicity of SARS-CoV-2 in a non-human primate model until 28 days after 39 virus inoculation. Cynomolgus macaques showed a fever after infection and X-ray radiographic 40 viral pneumonia was observed in one of three macaques. However, none of the macaques showed 41 life-threatening symptoms. A neutralizing antibody against SARS-CoV-2 and T-lymphocytes that 42 produced interferon (IFN)-γ and interleukin (IL)-2 specifically for SARS-CoV-2 protein were 43 detected on day 14 in the macaque that showed viral pneumonia. In the other macaques, in which a 44 neutralizing antibody was not detected, T-lymphocytes that produced IFN-γ specifically for 45 SARS-CoV-2 N protein increased on day 7 to day 14. These results suggest that not only a 46 neutralizing antibody but also cellular immunity augmented by IFN-γ has a role in the elimination 47 macaques showed clinical scores that reached a humane endpoint (Table S2) . Therefore, infection 122 with WK-521 induced mild clinical signs of disease that were varied in the macaques. 123 124 Viral pneumonia in macaques infected with SARS-CoV-2 125 Viral pneumonia and/or bronchopneumonia was observed in cynomolgus macaques infected with 126 SARS-CoV-2. Chest X-ray radiographs revealed a ground glass appearance in the lung, especially 127 in the peripheral pulmonary areas, of CE0324F from day 3 to day 7 but not after day 10 ( Fig. 2A-C) . 128

Saturation of percutaneous oxygen (SpO 2 ) values in infected macaques at each sampling were 129 higher than 90% during the study (Fig. S1B ). At autopsy on day 28, gross lesions were observed on 130 the surfaces of lungs including dark red and brown lesions in CE0324F, bright redness in CE0202M, 131 and small red areas in CE1242F (Fig. 2D-F) . 132

Histological pneumonia was observed in all of the macaques infected with WK-521. Thickened 133 alveolar walls with infiltration of macrophages were observed in the lung with the macroscopic 134 lesions in CE0324F, indicating a regenerative tissue (Fig. 3A) . A larger number of 135 bronchus-associated lymphoid tissues (BALT) were formed in the lung tissues of CE0324F (Fig.  136 3B) and CE1242F (Fig. S2A ) than in those of CE0202M ( Fig S2B) . In CE0202M, congestion and a 137 thrombus in the lung blood vessels were detected (Fig. 3D , E) and bronchopneumonia was detected 138 in CE1242F (Fig. 3F) . Lymphoid infiltration was detected in tissues other than respiratory organs. 139

Focal lymphoid accumulation was seen in the submandibular gland of CE0324F (Fig. 3C) . Thus, 140 although no virus was detected on day 28, lymphoid responses continued until day 28 after virus 141 inoculation. 142

Organ functions after infection with SARS-CoV-2 were biochemically analyzed. Levels 145 of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) in the plasma of CE0324F and 146 CE1242F were increased after virus infection, but their levels including total bilirubin were within 147 normal ranges, indicating minimal damage of the liver (Fig. 4A -C). No increase in the level of 148 blood urea nitrogen (BUN) or creatinine was detected, indicating normal kidney function after virus 149 infection (Fig. 4D , E). In CE0324F, the level of plasma amylase was temporally increased on day 1 150

The blood cell population in macaques infected with SARS-CoV-2 was examined. The 154 numbers of total white blood cells and granulocytes in CE0202M and CD1242F were increased 155 temporally on day 1, but the number of total white blood cells in CE0324F was decreased on days 1 156 and 3 and it was increased after day 14 ( Fig. 5A, B) . The numbers of lymphocytes in the blood of 157 CE0324F and CE1242F were decreased on day 1 and returned to the levels before infection on day 158 7 to day 10 ( Fig. 5C ), whereas the numbers of monocytes in CE0324F and CE1242F were increased 159 on day 7 and day 3, respectively (Fig. 5D ). The numbers of platelets in CE0324F and CE1242F 160 were decreased on day 3. Thus, two of three macaques (CE0324F and CE1242F) showed apparent 161 changes in the population of blood cells after SARS-CoV-2 infection. 162

Immune responses against SARS-CoV-2 in the cynomolgus macaques were examined. CE0324F 165 showed marked changes in plasma cytokine levels after infection (Fig. 6) . The levels of the 166 inflammatory cytokine interleukin-6 (IL-6) together with levels of monocyte chemotactic protein-1 167 (MCP-1) and IL-10 on day 1 were higher than those before infection. Levels of the Th2 cytokines 168 IL-4 and IL-13, Th17 cytokine IL-17, and chemokines MIP-1α were increased 10 days after virus 169 infection and the level of IL-8 was increased 21 days after virus infection, although the changes in 170 IL-17 and MIP-1α were small. Levels of the Th1 cytokines interferon-γ (IFN-γ) and IL-12 were 171 increased on day 1 after infection. IL-2 and TNF-α was detected in the plasma of CE0324F before 172 infection (day 0). CE1242F showed low cytokine responses in IL-6, MCP-1, IL-10, IL-4, IL-13, 173 MIP-1α, IFN-γ, and IL-12 compared with those in CE0324F. In CE0202M, levels of IL-8 and IL-12 174 on day 3 and levels of IL-13 from day 10 to day 17 were transiently increased, but no apparent 175 changes in other cytokines were detected during the study. 176

The neutralizing antibody against SARS-CoV-2 was detected in one macaque. A low titer of the 177 neutralizing antibody against WK-521 was detected in CE0324F on day 10 after virus inoculation, 178 but no neutralizing antibody was detected in the two other macaques until day 28 (Table 2 ). An IgG 179 response against SARS-CoV-2 S and N proteins was detected in the plasma of CE0324F and 180 CE1242F after day 14 and day 21, respectively, using an available antibody detection kit for human 181 IgG/IgM (Fig. S3) . No antibody response against SARS-CoV-2 was detected in CE0202M, in 182 which the number of BALTs was smaller than those in CE0324F and CE1242F, indicating a 183 relationship between IgG responses and BALT formation. 184 T lymphocyte responses specific for SARS-CoV-2 N protein were examined. In CE0324F, in 185 which the neutralizing antibody was detected, increases in the number of IL-2 and IFN-γ-producing cells specific for SARS-CoV-2 N protein were seen on day 14 after virus inoculation (Fig. 7) . In 187 CE0202M, increases in the number of IFN-γ-producing cells and IL-2-producing cells were 188 detected on day 14 and day 21, respectively. In CE1242F, increases in the number of 189 IFN-γ-producing cells and IL-2-producing cells were detected on day 7 and day 14, respectively. In 190 the two latter monkeys, the increase in the number of IL-2-producing cells followed that of 191 IFN-γ-producing cells and the stimulation indices of IFN-γ-producing cells were higher than those 192 of IL-2-producing cells. We also examined T-lymphocyte responses specific for SARS-CoV-2 N protein peptides. 216

In macaque CE0324F, in which the neutralizing antibody was detected, the number of cells 217 producing IFN-γ and IL-2 specific for SARS-CoV-2 N protein was increased 2 weeks after virus 218 inoculation. On the other hand, in CE0202M and CE1242F, in which no neutralizing antibody was 219 detected, an increase in the number of cells producing IL-2 specific for SARS-CoV-2 N protein 220 followed an increase in the number of cells producing IFN-γ. The results indicate that an IFN-γ 221 response with a low IL-2 response is not sufficient for induction of a neutralizing antibody. In 222 addition, the IFN-γ response (Th1 response) that helps so-called 'cellular immunity' might 223 contribute to elimination of SARS-CoV-2 without a neutralizing antibody. Another possibility is 224 that the early IFN-γ response in CE1242F was induced by memory Th1 cells, suggesting previous 225 exposure to the other coronaviruses. The effects of immunity against the common cold coronavirus 226 on SARS-CoV-2 infection will be analyzed using the macaque model in the future [31] . 227

The level of amylase in the plasma of CE0324F was temporally increased. It has been 228 reported that blood amylase was released from the injured pancreas in patients with COVID-19 229 pneumonia [32, 33] . However, we did not detect inflammation or necrosis in the pancreas of 230 macaques infected with SARS-CoV-2 at autopsy in the present study (data not shown). On the other 231 hand, lymphoid infiltration in the submandibular gland of CE0324F might be related to the increase 232 of plasma amylase [34], indicating that plasma amylase was derived from infected salivary glands 233 and that the virus detection in oral swab samples was due to virus propagation in the salivary glands 234 [35] . 235

In the present study, we revealed that SARS-CoV-2 propagated in the respiratory tissues 

A novel coronavirus from patients 349 with pneumonia in China

Clinical features of patients infected 352 with 2019 novel coronavirus in Wuhan

Clinical characteristics of 356 coronavirus disease 2019 in China

PubMed PMID: nonhuman primates infected with different H5N1 highly pathogenic avian influenza viruses